CD19-CD123 cCAR T-cells Therapy(iCell Gene Therapeutics)

N/A

Report date: 2024/04/02 11:48:19

Base Information

Drug NameCD19-CD123 cCAR T-cells Therapy(iCell Gene Therapeutics)

Drug Alias NameICG140CD19-CD123 cCAR T-cellsa chimeric antigen receptor (CAR) on the surface of T-cells directed against the target proteins CD19 and CD 123ICG140

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD123

TargetsB-lymphocyte antigen CD19Interleukin-3 receptor subunit alpha

Therapy Area/IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesiCell Gene Therapeutics LLC

China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLC

Inactive CompaniesN/A

Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A